STOCKHOLM, SWEDEN - 17 November 2022: AnaCardio today announces approval for the GOAL-HF1 Phase 1b/2a study from the competent authorities and ethics committees in Sweden, The Netherlands, Italy and the United Kingdom. T...

Read More

Leadership addition brings international financial and pharmaceutical experience to CRO Research Triangle Park, N.C. - August 31, 2022 – Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, mi...

Read More

CRO adds capacity to meet demands of rapidly growing large molecule market; sponsors benefit from minimal turnaround times, improved data delivery, faster decision-making, and more Research Triangle Park, N.C. - Augus...

Read More

New services and position added to CRO’s early phase business to better serve customers Research Triangle Park, N.C. - July 21, 2022 –Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, mi...

Read More

CRO gains access to genetic testing data, aims to improve global research with enhanced data insights and faster patient recruitment for rare disease studies Research Triangle Park, N.C. - July 12, 2022 –Worldwide C...

Read More

Global Phase I-IV CRO with specialization in Cardiovascular, Neuroscience, Oncology, and Rare Disease earns high marks based on ISR data for expertise, reliability, quality, and more; rated top-performing champion for ca...

Read More

State-of-the-art facility in Austin, Texas, enhances early phase research opportunities through new equipment and expertise, positioning CRO for further growth Research Triangle Park, N.C. - June 8, 2022 –Worldwide...

Read More

Corrigan will lead global direction and oversight of CRO’s quality and compliance programs Research Triangle Park, N.C. - May 3, 2022 – Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global,...

Read More